Frontiers in cancer nanomedicine: Directing mass transport through biological barriers

Trends in Biotechnology

Volumn 28, Issue 4, 2010, Pages 181-188

  Ferrari, Mauro ^a,b,c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Rice University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL BARRIER; BODY COMPARTMENTS; BUILDING BLOCKES; CELLULAR UPTAKE; CONVECTIVE TRANSPORT; DESIGN PARAMETERS; HEALTHY TISSUES; IMAGING CONTRAST; MASS TRANSPORT; NANOMEDICINES; SIDE EFFECT; SUB-CELLULAR;

ADHESION; CELL ADHESION; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; ONCOLOGY; SURFACE CHEMISTRY;

MASS TRANSFER;

ALBUMIN; ANTIFUNGAL AGENT; ANTISENSE OLIGONUCLEOTIDE; CONTRAST MEDIUM; CREMOPHOR; DOXORUBICIN; DRUG CARRIER; GOLD NANOPARTICLE; LIPOSOME; LOGIC EMBEDDED VECTOR; NANOCARRIER; NANOPARTICLE; NANOSHELL; RADIOPHARMACEUTICAL AGENT; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; CANCER TISSUE; CARDIOTOXICITY; CELL ADHESION; CELL TRANSPORT; CELLULAR DISTRIBUTION; CLINICAL TRIAL; HUMAN; MASS TRANSPORT; NANOMEDICINE; ONCOLOGY; PERMEABILITY BARRIER; PRIORITY JOURNAL; THERMODYNAMICS; TRANSPORT AND BINDING PHENOMENA;

ANTINEOPLASTIC AGENTS; HUMANS; NANOMEDICINE; NANOPARTICLES; NEOPLASMS;

EID: 77949632782     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibtech.2009.12.007     Document Type: Article

References (103)

1. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
2. Fidler I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 2003, 3:453-458.
3. Jain R.K. Transport of molecules, particles, and cells in solid tumors. Annu. Rev. Biomed. Eng. 1999, 1:241-263.
4. Jain R.K. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J. Natl. Cancer Inst. 1989, 81:570-576.
5. Sakamoto J., et al. Antibiological barrier nanovector technology for cancer applications. Expert Opin. Drug Deliv. 2007, 4:359-369.
6. Ferrari M. "Cancer Nanotechnology" in Cancer Medicine e.8, Hong, W.K., Bast, R.C. Jr, Hait, W., Kufe, D.W., Pollock, R.E., Weichselbaum, R.R., Holland, J.F., Frei III, E. (Eds.), BC Decker Inc, (In press). ISBN: 9781607950141.
7. Moghimi S.M., Davis S.S. Innovations in avoiding particle clearance from blood by Kupffer cells: 2010 cause for reflection. Crit. Rev. Ther. Drug Carrier Syst. 1994, 11:31-59.
8. Caliceti P., Veronese F.M. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev. 2003, 55:1261-1277.
9. Mehta D., Malik A.B. Signaling mechanisms regulating endothelial permeability. Physiol. Rev. 2006, 86:279-367.
10. Less J.R., et al. Interstitial hypertension in human breast and colorectal tumors. Cancer Res. 1992, 52:6371-6374.
11. Stohrer M., et al. Oncotic pressure in solid tumors is elevated. Cancer Res. 2000, 60:4251-4255.
12. Pluen A., et al. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:4628-4633.
13. Yuan F., et al. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 1994, 54:3352-3356.
14. Netti P.A., et al. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 2000, 60:2497-2503.
15. Brown E., et al. Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat. Med. 2003, 9:796-800.
16. McKee T.D., et al. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res. 2006, 66:2509-2513.
17. Mok W., et al. Matrix metalloproteinases-1 and -8 Improve the distribution and efficacy of an oncolytic virus. Cancer Res. 2007, 67:10664-10668.
18. Mok W., et al. Mathematical modeling of herpes simplex virus distribution in solid tumors: implications for cancer gene therapy. Clin. Cancer Res. 2009, 15:2352-2360.
19. Torchilin V.P. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu. Rev. Biomed. Eng. 2006, 8:343-375.
20. Majumdar S., Mitra A.K. Chemical modification and formulation approaches to elevated drug transport across cell membranes. Expert Opin. Drug Deliv. 2006, 3:511-527.
21. Folkman J. Fundamental concepts of the angiogenic process. Curr. Mol. Med. 2003, 3:643-651.
22. Undevia S.D., et al. Pharmacokinetic variability of anticancer agents. Nat. Rev. Cancer 2005, 5:447-458.
23. Hobbs S.K., et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:4607-4612.
24. Dellian M., et al. Vascular permeability in a human tumour xenograft: molecular charge dependence. Br. J. Cancer 2000, 82:1513-1518.
25. Sun C., et al. Non-uniform plasma leakage affects local hematocrit and blood flow: implications for inflammation and tumor perfusion. Ann. Biomed. Eng. 2007, 35:2121-2129.
26. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 2001, 41:189-207.
27. Iyer A.K., et al. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 2006, 11:812-818.
28. Sparreboom A., et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin. Cancer Res. 2005, 11:4136-4143.
29. Gradishar W.J. Albumin-bound nanoparticle paclitaxel. Clin. Adv. Hematol. Oncol. 2005, 3:348-349.
30. Stroh M., et al. Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nat. Med. 2005, 11:678-682.
31. Rosen M.A., Schnall M.D. Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma. Clin. Cancer Res. 2007, 13:770s-776s.
32. Minchinton A.I., Tannock I.F. Drug penetration in solid tumours. Nat. Rev. Cancer 2006, 6:583-592.
33. Hoshii T., et al. Evaluation of magnetic resonance imaging-based prostate-specific antigen density of the prostate in the diagnosis of prostate cancer. Int. J. Urol. 2007, 14:305-310.
34. Koyama Y., et al. In vivo molecular imaging to diagnose and subtype tumors through receptor-targeted optically labeled monoclonal antibodies. Neoplasia 2007, 9:1021-1029.
35. Barrett T., et al. In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies. Clin. Cancer Res. 2007, 13:6639-6648.
36. Riehemann K., et al. Nanotechnology - challenge and opportunity in clinical applications. Angew. Chem. Int. Ed. Engl. 2009, 48:872-897.
37. Decuzzi P., et al. A theoretical model for the margination of particles within blood vessels. Ann. Biomed. Eng. 2005, 33:179-190.
38. Gentile F., et al. The effect of shape on the margination dynamics of non-neutrally buoyant particles in two-dimensional shear flows. J. Biomech. 2008, 41:2312-2318.
39. Lee S.Y., et al. Design of bio-mimetic particles with enhanced vascular interaction. J. Biomech. 2009, 42:1885-1890.
40. Decuzzi P., Ferrari M. The adhesive strength of non-spherical particles mediated by specific interactions. Biomaterials 2006, 27:5307-5314.
41. Decuzzi P., Ferrari M. The role of specific and non-specific interactions in receptor-mediated endocytosis of nanoparticles. Biomaterials 2007, 28:2915-2922.
42. Decuzzi P., Ferrari M. The receptor-mediated endocytosis of nonspherical particles. Biophys J. 2008, 94:3790-3797.
43. Decuzzi P., Ferrari M. Design maps for nanoparticles targeting the diseased microvasculature. Biomaterials 2008, 29:377-384.
44. Godin B. et al.: An integrated approach for the rational design of nanovectors for biomedical imaging and therapy. In: Pasqulini R., Arap W. (Eds.) Advances in genetics. Elsevier, 2010, in press.
45. Decuzzi P., et al. Intravascular delivery of particulate systems: Does geometry really matter?. Pharm Res. 2009, 26:235-243.
46. Sanga S., et al. Mathematical modeling of cancer progression and response to chemotherapy. Expert Rev. Anticancer Ther. 2006, 6:1361-1376.
47. Ferrari M. The mathematical engines of nanomedicine. Small 2008, 4:20-25.
48. Tasciotti E., et al. Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nature Nanotechnology 2008, 3:151-157.
49. Serda R.E., et al. The association of silicon microparticles with endothelial cells in drug delivery to the vasculature. Biomaterials 2009, 30:2440-2448.
50. Serda R.E., et al. Mitotic trafficking of silicon microparticles. Nanoscale 2009, 1:250-259.
51. Decuzzi P., et al. The effective dispersion of nanovectors within the tumor microvasculature. Ann. Biomed Eng. 2006, 34:633-641.
52. Decuzzi P. et al. Size and Shape Effects in the Biodistribution of nano-Particle Systems, J. Control Rel. 2009, 2009, in press. doi:10.1016/j.jconrel.2009.10.014.
53. Ferrari M. Nanogeometry: Beyond drug delivery. Nature Nanotechnology 2008, 3:131-132.
54. Morikawa K., et al. Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res. 1988, 48:6863-6871.
55. Fidler I.J. Critical determinants of metastasis. Semin Cancer Biol. 2002, 12:89-96.
56. Howe A., et al. Integrin signaling and cell growth control. Curr. Opin. Cell Biol. 1998, 10:220-231.
57. Kumar S, Weaver VM. Mechanics, malignancy, and metastasis: The force journey of a tumor cell. Cancer Metastasis Rev. 2009 Jan 21.[Epub ahead of print].
58. Johnsen M., et al. Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr. Opin. Cell Biol. 1998, 10:667-671.
59. Karadag A., et al. Dentin matrix protein 1 enhances invasion potential of colon cancer cells by bridging matrix metalloproteinase-9 to integrins and CD44. Cancer Res. 2005, 65:11545-11552.
60. Butcher D.T., et al. A tense situation: forcing tumour progression. Nat. Rev. Cancer 2009, 9:108-122.
61. Kumar S, Weaver VM. Mechanics, malignancy, and metastasis: The force journey of a tumor cell. Cancer Metastasis Rev. 2009, [Epub ahead of print].
62. Sato M., et al. Molecular targets on blood vessels for cancer therapies in clinical trials. Oncology 2007, 21:1346-1352.
63. Tandle A., et al. Tumor vasculature-targeted delivery of tumor necrosis factor-alpha. Cancer 2009, 115:128-139.
64. Epenetos A.A., et al. Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms. Cancer Res. 1986, 46:3183-3191.
65. Khawli L.A., et al. Effect of seven new vasoactive immunoconjugates on the enhancement of monoclonal antibody uptake in tumors. Cancer 1994, 73:824-831.
66. Slamon D.J., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344:783-792.
67. Langer R. Drug delivery and targeting. Nature 1998, 392:5-10.
68. Langer R. Drug delivery. Drugs on target. Science 2001, 293:58-59.
69. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 2005, 5:161-171.
70. Peer D., et al. Nanocarriers: Emerging platforms for cancer therapy. Nature Nanotechnology 2007, 2:751-760.
71. Tanaka T., et al. nanotechnology for breast cancer therapy. Biomedical Microdevices 2009, 11:49-63.
72. Moen M.D., et al. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs 2009, 69:361-392.
73. Campos S. Liposomal anthracyclines: adjuvant and neoadjuvant therapy for breast cancer. Oncologist 2003, 8(Suppl 2):10-16.
74. Lyass O., et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000, 89:1037-1047.
75. Henderson I.C., Bhatia V. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy. Expert Rev. Anticancer Ther. 2007, 7:919-943.
76. Gradishar W.J. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin. Pharmacother. 2006, 7:1041-1053.
77. Zhang L., et al. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther. 2008, 83:761-769.
78. Lu Y., et al. Folate receptor-targeted immunotherapy: induction of humoral and cellular immunity against hapten-decorated cancer cells. Int. J. Cancer 2005, 116:710-719.
79. Muller C., et al. Preclinical evaluation of novel organometallic 99mTc-folate and 99mTc-pteroate radiotracers for folate receptor-positive tumour targeting. Eur. J. Nucl. Med. Mol. Imaging 2006, 33:1007-1016.
80. Yang X., Gorenstein D.G. Progress in thioaptamer development. Curr. Drug Targets 2004, 5:705-715.
81. Pan X., Lee R.J. Tumour-selective drug delivery via folate receptor-targeted liposomes. Expert Opin. Drug Deliv. 2004, 1:7-17.
82. Shi X., et al. Dendrimer-entrapped gold nanoparticles as a platform for cancer-cell targeting and imaging. Small 2007, 3:1245-1252.
83. Rivera E. Liposomal anthracyclines in metastatic breast cancer: clinical update. Oncologist 2003, 8(Suppl 2):3-9.
84. Duncan R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2003, 2:347-360.
85. Green J.J., et al. Electrostatic ligand coatings of nanoparticles enable ligand-specific gene delivery to human primary cells. Nano. Lett. 2007, 7:874-879.
86. Cloninger M.J. Biological applications of dendrimers. Curr. Opin. Chem. Biol. 2002, 6:742-748.
87. Hirsch L.R., et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:13549-13554.
88. Loo C., et al. Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano. Lett. 2005, 5:709-711.
89. Yong K.T., et al. Quantum rod bioconjugates as targeted probes for confocal and two-photon fluorescence imaging of cancer cells. Nano. Lett. 2007, 7:761-765.
90. Kam N.W., et al. Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:11600-11605.
91. Yan F., Kopelman R. The embedding of meta-tetra(hydroxyphenyl)-chlorin into silica nanoparticle platforms for photodynamic therapy and their singlet oxygen production and pH-dependent optical properties. Photochem. Photobiol. 2003, 78:587-591.
92. Martin F.J., et al. Acute toxicity of intravenously administered microfabricated silicon dioxide drug delivery particles in mice: preliminary findings. Drugs R. D. 2005, 6:71-81.
93. Peng J., et al. An antisense oligonucleotide carrier based on amino silica nanoparticles for antisense inhibition of cancer cells. Nanomedicine 2006, 2:113-120.
94. Oyewumi M.O., Mumper R.J. Engineering tumor-targeted gadolinium hexanedione nanoparticles for potential application in neutron capture therapy. Bioconjug. Chem. 2002, 13:1328-1335.
95. Yan F., et al. Synthesis and characterization of silica-embedded iron oxide nanoparticles for magnetic resonance imaging. J. Nanosci. Nanotechnol. 2004, 4:72-76.
96. Gabizon A., Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 1997, 54(Suppl 4):15-21.
97. Gabizon A., et al. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv. Drug Deliv. Rev. 2004, 56:1177-1192.
98. Sanhai W.R., et al. Seven challenges for nanomedicine. Nature Nanotechnology 2008, 3:242-244.
99. Lal S., et al. Nanoshell-enabled photothermal cancer therapy: impending clinical impact. Acc Chem Res. 2008, 41:1842-1851.
100. Derfus A.M., et al. Remotely triggered release from magnetic nanoparticles. Advanced Materials 2007, 19:3932-3936.
101. Maier-Hauff K., et al. Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: results of a feasibility study on patients with glioblastoma multiforme. J. Neurooncol. 2007, 81:53-60.
102. Curley S.A. Radiofrequency ablation of malignant liver tumors. Ann. Surg. Oncol. 2003, 10:338-347.
103. Gannon C.J., et al. Carbon nanotube-enhanced thermal destruction of cancer cells in a noninvasive radiofrequency field. Cancer 2007, 110:2654-2665.